Public Consultation on a Proposed Framework for Oversight of Dual Use Life Sciences Research, 36341-36343 [E8-14438]
Download as PDF
rfrederick on PROD1PC67 with NOTICES
Federal Register / Vol. 73, No. 124 / Thursday, June 26, 2008 / Notices
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892. (Telephone
Conference Call).
Contact Person: Carol J. Goter-Robinson,
PhD, Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 748, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452,
(301) 594–7791,
goterrobinsonc@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Multi-Center
Clinical Studies Planning Grants in
Hepatology.
Date: July 25, 2008.
Time: 4 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Maria E. Davila-Bloom,
PhD, Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 758, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–7637, davilabloomm@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Endoscopic
Research in Pancreatic and Billiary Disease.
Date: July 28, 2008.
Time: 1 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Thomas A. Tatham, PhD,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 760, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–3993,
tathamt@mail.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Polycystic Kidney
Disease Program Projects.
Date: August 8, 2008.
Time: 9 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: Carol J. Goter-Robinson,
PhD, Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 748, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452,
(301) 594–7791,
goterrobinsonc@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
VerDate Aug<31>2005
15:05 Jun 25, 2008
Jkt 214001
Dated: June 20, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–14546 Filed 6–25–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Child Health and
Human Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel; Regulation of
Placental Signaling and Function by
Maternal Nutrient Availability.
Date: July 24, 2008.
Time: 2 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6100
Executive Boulevard, Room 5B01, Rockville,
MD 20852, (Telephone Conference Call).
Contact Person: Gopal M. Bhatnagar, PhD,
Scientific Review Administrator, National
Institute of Child Health and Human
Development, National Institutes of Health,
6100 Bldg Rm 5B01, Rockville, MD 20852,
(301) 435–6889, bhatnagg@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: June 20, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–14548 Filed 6–25–08; 8:45 am]
PO 00000
Frm 00047
Fmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; Training SEP.
Date: July 18, 2008.
Time: 2 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Shanta Rajaram, PhD,
Scientific Review Administrator, Scientific
Review Branch, Division of Extramural
Research, NINDS/NIH/DHHS/Neuroscience
Center, 6001 Executive Blvd., Suite 3208,
Msc9529, Bethesda, MD 20852, (301) 435–
6033, rajarams@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: June 20, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–14553 Filed 6–25–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Public Consultation on a Proposed
Framework for Oversight of Dual Use
Life Sciences Research
AGENCY:
National Institutes of Health,
HHS.
BILLING CODE 4140–01–P
Sfmt 4703
36341
E:\FR\FM\26JNN1.SGM
26JNN1
36342
Federal Register / Vol. 73, No. 124 / Thursday, June 26, 2008 / Notices
Notice of Public Consultation
Meeting.
ACTION:
SUMMARY: The Federal Government is
sponsoring a public consultation to
engage the scientific community and
research organizations in a discussion of
a framework for the oversight of dual
use life sciences research proposed by
the National Science Advisory Board for
Biosecurity (NSABB), which is an
advisory committee to the Federal
Government. In its report, the NSABB
posed a series of questions on which the
Board encouraged the Federal
Government to solicit public comment.
These questions concerned such matters
as the clarity of the criteria proposed by
the Board for identifying dual use
research of concern, institutional
oversight responsibilities, who should
make determinations regarding dual use
research of concern, and how to balance
appropriate controls with academic
freedom and scientific exchange. This
public consultation is an opportunity
for members of the scientific community
and general public to provide input on
these important issues.
The one day public
consultation will be held on July 15,
2008, from 8:30 a.m. to 5 p.m.
ADDRESSES: The public meeting will be
held on the National Institutes of Health
(NIH) campus. The meeting will be in
the Natcher Conference Center, Building
45, Balcony B. The NIH is located at
9000 Rockville Pike, Bethesda,
Maryland. There is a metro stop on the
NIH campus—Medical Center Station
on the Red Line. The Natcher Center is
a very short walk from the Metro station
and a campus shuttle is also available.
FOR FURTHER INFORMATION CONTACT: Ms.
Ronna Hill, NIH Office of Biotechnology
Activities, by e-mail at
hillro@od.nih.gov or by telephone at
301–435–2137. Faxes may be sent to the
NIH Office of Biotechnology Activities
at 301–496–9839.
SUPPLEMENTARY INFORMATION:
rfrederick on PROD1PC67 with NOTICES
DATE AND TIME:
Background
The Federal Government is
sponsoring a public consultation to
engage the scientific community and
research organizations in a discussion of
a framework for the oversight of dual
use life sciences research proposed by
the NSABB. The proposed framework
(accessible at https://
www.biosecurityboard.gov/news.asp),
which has been formally submitted by
the Board to the Federal Government for
its consideration, outlines key features
of oversight of dual use research,
including criterion for identifying dual
use research of concern, local oversight,
VerDate Aug<31>2005
15:05 Jun 25, 2008
Jkt 214001
evaluation and risk assessment of
research with dual use potential,
responsible communication of research
with dual use potential, considerations
in developing codes of conduct, and the
need for outreach and education. The
proposed framework also outlines the
roles and responsibilities of key
individuals and institutions in
managing dual use research, including
researchers, research institutions,
institutional review entities, the
NSABB, and the Federal Government.
The public consultation meeting will
focus on a set of questions, included in
Appendix 2 of the proposed framework,
on which the USG and the NSABB
would specifically like to solicit
comment. These questions concern such
matters as the clarity of the criterion
proposed by the Board for identifying
dual use research of concern;
institutional oversight responsibilities,
including how to balance appropriate
controls with academic freedom and
scientific exchange; and approaches to
education to enhance awareness of the
issue.
The meeting will be conducted as a
series of panels where invited speakers
and meeting attendees will be asked to
discuss particular topics of interest to
the Government. Each panel will
include ample time for in-depth
discussion of the issues surrounding
each topic. The three panels will focus
on: (1) The criterion for identifying dual
use research of concern and associated
guidance, (2) the process for
identification and oversight of dual use
research of concern, and (3) awarenessraising and educational resources.
Explanation of and discussion questions
for each panel follow:
Panel I: ‘‘Criterion for Identifying Dual
Use Research of Concern’’
The NSABB proposed a criterion for
identifying ‘‘dual use research of
concern,’’ i.e., that research with the
highest potential for yielding
knowledge, products, or technology that
could be misapplied to threaten public
health or other aspects of national
security. The proposed criterion is:
‘‘Research that, based on current
understanding, can be reasonably
anticipated to provide knowledge,
products, or technologies that could be
directly misapplied by others to pose a
threat to public health and safety,
agriculture, plants, animals, the
environment, or materiel.’’
In the NSABB report, the criterion is
accompanied by guidance that provides
examples of research that deserves
especially careful consideration with
regard to the applicability of the
criterion. The guidance is not meant to
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
be definitive in identifying dual use
research of concern, but rather to serve
as a tool for focusing attention and
evaluation. The U.S. Government is
seeking input on the utility of the
criterion and the accompanying
guidance and on how they could be
implemented. The following questions
will be discussed in Panel I:
• Is the criterion sufficiently specific
and understandable so that it can be
applied consistently? If not, how could
it be improved?
• Is the criterion too broad? Will the
criterion capture research that is not
appropriately considered dual use of
concern? If so, what are some examples
of research that would be
inappropriately captured?
• Is the criterion too narrow? Might it
fail to include research that should be
considered dual use of concern? How
might it be modified to be more
appropriately encompassing?
• Is the guidance that follows the
criterion for identifying dual use
research of concern helpful and
sufficient? Is it clear and
understandable? Should additional
categories of research that may yield
dual use findings of concern be
included in the guidance?
• What share of research at your
institution would likely be captured
with the proposed criterion for dual use
research of concern?
Panel II: ‘‘Responsibilities and Process
for the Identification and Oversight of
Dual Use Research of Concern’’
Everyone involved in life sciences
research has a responsibility for
identifying and responding
appropriately to dual use research of
concern. The NSABB has put forth
recommendations regarding the general
framework within which these
responsibilities for oversight would be
carried out. The Federal Government
must determine how to translate those
recommendations into policies and
requirements that would apply to
investigators, other laboratory staff,
senior research administrators,
institutional review committees, and
other parties. Toward that end, the
government is seeking input on the
following matters:
Investigator Responsibilities
• Should the principal investigator
bear primary responsibility for making
the initial determination as to whether
his or her research might be considered
dual use of concern?
I If so, how should that
determination be made?
Æ Should the determination routinely
include input from others? If so, who
E:\FR\FM\26JNN1.SGM
26JNN1
Federal Register / Vol. 73, No. 124 / Thursday, June 26, 2008 / Notices
else should participate in the initial
evaluation?
Æ To whom should the investigator
report this determination?
I If not, who should make this
determination?
Institutional Review Responsibilities
• What are the characteristics of a
dual use research review committee?
What expertise will be needed?
• How should institutional review
responsibilities be fulfilled?
I Should institutions be required to
establish their own review committees?
Æ Can existing institutional review
committees fulfill these characteristics
(e.g., the Institutional Biosafety
Committee) as is or with some
modification?
Æ If the IBC, what additional
expertise would be needed to facilitate
the review of dual use research of
concern?
Æ Would most institutions likely have
the necessary in-house expertise for this
review?
Æ Would it be helpful to have the
option of utilizing a commercial review
entity or the review entity at another
institution?
I Should regional committees or a
national committee be established
Æ As optional review mechanisms?
Æ In lieu of a requirement to establish
committees at the institutional level?
Æ In an advisory capacity (e.g., the
NIH RAC) to give recommendations on
specific protocols, leaving final
approval authority with the institutions?
Æ How much of a burden would this
proposed oversight system pose to your
institution?
rfrederick on PROD1PC67 with NOTICES
Panel III: ‘‘Guidance and Educational
Resources Needed To Assist the
Research Community in its Fulfillment
of Oversight Responsibilities for Dual
Use Research’’
Since the outset of its deliberations,
the NSABB has noted the importance of
awareness in dealing effectively with
dual use research and the need for more
outreach and education on this issue,
particularly to the investigator
community, where various studies
document a low level of awareness. In
its report, the NSABB makes a number
of observations and recommendations
for promoting awareness, as well as
receiving stakeholder input on evolving
policies. The NSABB also views several
elements of the oversight framework—
the code of conduct, communications
guidance, and the guidance on
identifying dual use research—as key
educational tools. The U.S. Government
is seeking input on the following
matters:
VerDate Aug<31>2005
15:05 Jun 25, 2008
Jkt 214001
• Has the NSABB identified the major
educational and outreach priorities in
its report (pages 29–31)? If not, what
other priorities should there be?
• How might the following elements
of the Oversight Framework be used as
educational tools:
I Criterion and associated guidance.
I Guidance on responsible
communication of dual use research of
concern.
I Code of conduct.
• What other kinds of educational
resources, tools, and strategies would be
helpful or particularly effective in
educating various audiences, such as
investigators, research administration,
biosafety staff, and others?
This public consultation is open to
the public and is free of charge. Preregistration is encouraged, however, due
to limited space. To pre-register, please
access the pre-registration link at
https://www.biosecurityboard.gov/
meetings.asp.
Any groups or individuals who
cannot attend the meeting are
encouraged to submit written comments
in advance of the meeting to Mr. Allan
Shipp, NIH Office of Biotechnology
Activities by e-mail at
shippa@od.nih.gov or by Fax at 301–
496–9839.
Dated: June 19, 2008.
Amy P. Patterson,
Director, Office of Biotechnology Activities,
National Institutes of Health.
[FR Doc. E8–14438 Filed 6–25–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
[Docket No. DHS–2008–0067]
The National Infrastructure Advisory
Council
Directorate for National
Protection and Programs, Department of
Homeland Security.
ACTION: Committee Management; Notice
of Federal Advisory Council Meeting.
AGENCY:
SUMMARY: The National Infrastructure
Advisory Council will meet on Tuesday
July 8, 2008 in Washington, DC. The
meeting will be open to the public.
Notice of this meeting was previously
published in the Federal Register to
permit timely solicitation of public
comment. This notice provides the
meeting location. This notice is being
published less than 15 days before the
date of the meeting because the meeting
location has just been finalized.
DATES: The National Infrastructure
Advisory Council will meet Tuesday,
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
36343
July 8, 2008 from 1:30 p.m. to 4:30 p.m.
Please note that the meeting may close
early if the committee has completed its
business. For additional information,
please consult the NIAC Web site,
https://www.dhs.gov/niac, or contact
Timothy McCabe by phone at 703–235–
2888 or by e-mail at
timothy.mccabe@associates.dhs.gov.
ADDRESSES: The meeting will be held at
the Ritz-Carlton Hotel’s Salon I, 1150
22nd Street, NW., Washington, DC
20037. While we will be unable to
accommodate oral comments from the
public, written comments may be sent
to Carlos Kizzee, Department of
Homeland Security, Directorate for
National Protection and Programs,
Washington, DC 20528. Written
comments should reach the contact
person listed no later than July 1, 2008.
Comments must be identified by DHS–
2008–0067 and may be submitted by
one of the following methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• E-mail:
timothy.mccabe@associates.dhs.gov.
Include the docket number in the
subject line of the message.
• Fax: 703–235–3055.
• Mail: Carlos Kizzee, Department of
Homeland Security, Directorate for
National Protection and Programs,
Washington, DC 20528.
Instructions: All submissions received
must include the words ‘‘Department of
Homeland Security’’ and the docket
number for this action. Comments
received will be posted without
alteration at https://www.regulations.gov,
including any personal information
provided.
Docket: For access to the docket to
read background documents or
comments received by the National
Infrastructure Advisory Council, go to
https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Carlos Kizzee, NIAC Designated Federal
Officer, Department of Homeland
Security, Washington, DC 20528;
telephone 703–235–2888.
SUPPLEMENTARY INFORMATION: Notice of
this meeting is given under the Federal
Advisory Committee Act, 5 U.S.C. App.
(Pub. L. 92–463). The National
Infrastructure Advisory Council shall
provide the President through the
Secretary of Homeland Security with
advice on the security of the critical
infrastructure sectors and their
information systems.
The National Infrastructure Advisory
Council will meet to address issues
relevant to the protection of critical
infrastructure as directed by the
E:\FR\FM\26JNN1.SGM
26JNN1
Agencies
[Federal Register Volume 73, Number 124 (Thursday, June 26, 2008)]
[Notices]
[Pages 36341-36343]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-14438]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Consultation on a Proposed Framework for Oversight of Dual
Use Life Sciences Research
AGENCY: National Institutes of Health, HHS.
[[Page 36342]]
ACTION: Notice of Public Consultation Meeting.
-----------------------------------------------------------------------
SUMMARY: The Federal Government is sponsoring a public consultation to
engage the scientific community and research organizations in a
discussion of a framework for the oversight of dual use life sciences
research proposed by the National Science Advisory Board for
Biosecurity (NSABB), which is an advisory committee to the Federal
Government. In its report, the NSABB posed a series of questions on
which the Board encouraged the Federal Government to solicit public
comment. These questions concerned such matters as the clarity of the
criteria proposed by the Board for identifying dual use research of
concern, institutional oversight responsibilities, who should make
determinations regarding dual use research of concern, and how to
balance appropriate controls with academic freedom and scientific
exchange. This public consultation is an opportunity for members of the
scientific community and general public to provide input on these
important issues.
DATE AND TIME: The one day public consultation will be held on July 15,
2008, from 8:30 a.m. to 5 p.m.
ADDRESSES: The public meeting will be held on the National Institutes
of Health (NIH) campus. The meeting will be in the Natcher Conference
Center, Building 45, Balcony B. The NIH is located at 9000 Rockville
Pike, Bethesda, Maryland. There is a metro stop on the NIH campus--
Medical Center Station on the Red Line. The Natcher Center is a very
short walk from the Metro station and a campus shuttle is also
available.
FOR FURTHER INFORMATION CONTACT: Ms. Ronna Hill, NIH Office of
Biotechnology Activities, by e-mail at hillro@od.nih.gov or by
telephone at 301-435-2137. Faxes may be sent to the NIH Office of
Biotechnology Activities at 301-496-9839.
SUPPLEMENTARY INFORMATION:
Background
The Federal Government is sponsoring a public consultation to
engage the scientific community and research organizations in a
discussion of a framework for the oversight of dual use life sciences
research proposed by the NSABB. The proposed framework (accessible at
https://www.biosecurityboard.gov/news.asp), which has been formally
submitted by the Board to the Federal Government for its consideration,
outlines key features of oversight of dual use research, including
criterion for identifying dual use research of concern, local
oversight, evaluation and risk assessment of research with dual use
potential, responsible communication of research with dual use
potential, considerations in developing codes of conduct, and the need
for outreach and education. The proposed framework also outlines the
roles and responsibilities of key individuals and institutions in
managing dual use research, including researchers, research
institutions, institutional review entities, the NSABB, and the Federal
Government.
The public consultation meeting will focus on a set of questions,
included in Appendix 2 of the proposed framework, on which the USG and
the NSABB would specifically like to solicit comment. These questions
concern such matters as the clarity of the criterion proposed by the
Board for identifying dual use research of concern; institutional
oversight responsibilities, including how to balance appropriate
controls with academic freedom and scientific exchange; and approaches
to education to enhance awareness of the issue.
The meeting will be conducted as a series of panels where invited
speakers and meeting attendees will be asked to discuss particular
topics of interest to the Government. Each panel will include ample
time for in-depth discussion of the issues surrounding each topic. The
three panels will focus on: (1) The criterion for identifying dual use
research of concern and associated guidance, (2) the process for
identification and oversight of dual use research of concern, and (3)
awareness-raising and educational resources. Explanation of and
discussion questions for each panel follow:
Panel I: ``Criterion for Identifying Dual Use Research of Concern''
The NSABB proposed a criterion for identifying ``dual use research
of concern,'' i.e., that research with the highest potential for
yielding knowledge, products, or technology that could be misapplied to
threaten public health or other aspects of national security. The
proposed criterion is: ``Research that, based on current understanding,
can be reasonably anticipated to provide knowledge, products, or
technologies that could be directly misapplied by others to pose a
threat to public health and safety, agriculture, plants, animals, the
environment, or materiel.''
In the NSABB report, the criterion is accompanied by guidance that
provides examples of research that deserves especially careful
consideration with regard to the applicability of the criterion. The
guidance is not meant to be definitive in identifying dual use research
of concern, but rather to serve as a tool for focusing attention and
evaluation. The U.S. Government is seeking input on the utility of the
criterion and the accompanying guidance and on how they could be
implemented. The following questions will be discussed in Panel I:
Is the criterion sufficiently specific and understandable
so that it can be applied consistently? If not, how could it be
improved?
Is the criterion too broad? Will the criterion capture
research that is not appropriately considered dual use of concern? If
so, what are some examples of research that would be inappropriately
captured?
Is the criterion too narrow? Might it fail to include
research that should be considered dual use of concern? How might it be
modified to be more appropriately encompassing?
Is the guidance that follows the criterion for identifying
dual use research of concern helpful and sufficient? Is it clear and
understandable? Should additional categories of research that may yield
dual use findings of concern be included in the guidance?
What share of research at your institution would likely be
captured with the proposed criterion for dual use research of concern?
Panel II: ``Responsibilities and Process for the Identification and
Oversight of Dual Use Research of Concern''
Everyone involved in life sciences research has a responsibility
for identifying and responding appropriately to dual use research of
concern. The NSABB has put forth recommendations regarding the general
framework within which these responsibilities for oversight would be
carried out. The Federal Government must determine how to translate
those recommendations into policies and requirements that would apply
to investigators, other laboratory staff, senior research
administrators, institutional review committees, and other parties.
Toward that end, the government is seeking input on the following
matters:
Investigator Responsibilities
Should the principal investigator bear primary
responsibility for making the initial determination as to whether his
or her research might be considered dual use of concern?
[squf] If so, how should that determination be made?
[cir] Should the determination routinely include input from others?
If so, who
[[Page 36343]]
else should participate in the initial evaluation?
[cir] To whom should the investigator report this determination?
[squf] If not, who should make this determination?
Institutional Review Responsibilities
What are the characteristics of a dual use research review
committee? What expertise will be needed?
How should institutional review responsibilities be
fulfilled?
[squf] Should institutions be required to establish their own
review committees?
[cir] Can existing institutional review committees fulfill these
characteristics (e.g., the Institutional Biosafety Committee) as is or
with some modification?
[cir] If the IBC, what additional expertise would be needed to
facilitate the review of dual use research of concern?
[cir] Would most institutions likely have the necessary in-house
expertise for this review?
[cir] Would it be helpful to have the option of utilizing a
commercial review entity or the review entity at another institution?
[squf] Should regional committees or a national committee be
established
[cir] As optional review mechanisms?
[cir] In lieu of a requirement to establish committees at the
institutional level?
[cir] In an advisory capacity (e.g., the NIH RAC) to give
recommendations on specific protocols, leaving final approval authority
with the institutions?
[cir] How much of a burden would this proposed oversight system
pose to your institution?
Panel III: ``Guidance and Educational Resources Needed To Assist the
Research Community in its Fulfillment of Oversight Responsibilities for
Dual Use Research''
Since the outset of its deliberations, the NSABB has noted the
importance of awareness in dealing effectively with dual use research
and the need for more outreach and education on this issue,
particularly to the investigator community, where various studies
document a low level of awareness. In its report, the NSABB makes a
number of observations and recommendations for promoting awareness, as
well as receiving stakeholder input on evolving policies. The NSABB
also views several elements of the oversight framework--the code of
conduct, communications guidance, and the guidance on identifying dual
use research--as key educational tools. The U.S. Government is seeking
input on the following matters:
Has the NSABB identified the major educational and
outreach priorities in its report (pages 29-31)? If not, what other
priorities should there be?
How might the following elements of the Oversight
Framework be used as educational tools:
[squf] Criterion and associated guidance.
[squf] Guidance on responsible communication of dual use research
of concern.
[squf] Code of conduct.
What other kinds of educational resources, tools, and
strategies would be helpful or particularly effective in educating
various audiences, such as investigators, research administration,
biosafety staff, and others?
This public consultation is open to the public and is free of
charge. Pre-registration is encouraged, however, due to limited space.
To pre-register, please access the pre-registration link at https://
www.biosecurityboard.gov/meetings.asp.
Any groups or individuals who cannot attend the meeting are
encouraged to submit written comments in advance of the meeting to Mr.
Allan Shipp, NIH Office of Biotechnology Activities by e-mail at
shippa@od.nih.gov or by Fax at 301-496-9839.
Dated: June 19, 2008.
Amy P. Patterson,
Director, Office of Biotechnology Activities, National Institutes of
Health.
[FR Doc. E8-14438 Filed 6-25-08; 8:45 am]
BILLING CODE 4140-01-P